SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
INCY reported Third Quarter 2026 results. The stock moved -0.1% on the print.
INCYearnings

Earnings reactions, page 9

Incyte (INCY) Q3 FY2026 earnings

October 29, 2026 · SharpeIQ Research Desk

Reported results

  • Jakafi/Jakafi XR net sales were $827 million in the third quarter of 2026.
  • Opzelura cream net sales were $255 million in the third quarter of 2026.
  • Hematology and Oncology portfolio net sales were $235 million in the third quarter of 2026.
  • GAAP research and development expenses were $1.79 billion and non-GAAP research and development expenses were $1.75 billion for the third quarter of 2026.
  • GAAP SG&A expenses were $364.3 million and non-GAAP SG&A expenses were $339.1 million for the third quarter of 2026.
  • GAAP and non-GAAP cost of sales were $108.7 million and $102.2 million, respectively, for the third quarter of 2026.

Guidance

  • Full year 2026 Opzelura net sales guidance: $1,100 - $1,120 million
  • Full year 2026 Hematology and Oncology net sales guidance: $890 - $910 million
  • Full year 2026 total net sales guidance: $5,210 - $5,300 million

Notes

The third quarter of 2026 includes a one-time $1.23 billion IPR&D expense related to the acquisition of Vega Therapeutics.

Price and volatility reaction

The stock moved -0.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -5.1 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release116.872026-10-28
Close after release116.82026-10-29
Realised move-0.1%close to close
30d ATM IV change-5.1 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →